{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:44Z","timestamp":1791500024979,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105639","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:43:00Z","timestamp":1791319380000},"page":"105639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The efficacy of immune-checkpoint inhibitors in combination with definitive chemoradiotherapy in non-metastatic esophageal SCC: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-2019","authenticated-orcid":false,"given":"Reza","family":"Ghalehtaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4196-7981","authenticated-orcid":false,"given":"Alireza","family":"Shariati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8798-3278","authenticated-orcid":false,"given":"Zahra","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Mahdi","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-8440","authenticated-orcid":false,"given":"Romina","family":"Abyaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.critrevonc.2026.105639_bib1","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/cncr.35561","article-title":"Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: a review","volume":"130","author":"Abyaneh","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105639_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102471","article-title":"Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial","volume":"69","author":"Ai","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105639_bib3","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"BMJ Ment. Health"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105639_bib4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s43018-025-00918-1","article-title":"Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma \u2013 a multicenter phase 2 trial (EPOC1802)","volume":"6","author":"Bando","year":"2025","journal-title":"Nat. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105639_bib5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105639_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41467-024-46307-7","article-title":"Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab","volume":"15","author":"Chen","year":"2024","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105639_bib9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO-25-03044","article-title":"Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, phase II trial (EC-CRT-002)","volume":"44","author":"Chen","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105639_bib10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jcma.2017.06.014","article-title":"Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy","volume":"80","author":"Chen","year":"2017","journal-title":"J. Chin. Med. Assoc."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105639_bib11","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1093\/oncolo\/oyad094","article-title":"Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy","volume":"28","author":"Cheng","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105639_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125905","article-title":"Mechanistic rationales for combining immunotherapy with radiotherapy","volume":"14","author":"Chi","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105639_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105639_bib14","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.ejso.2021.02.001","article-title":"Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer","volume":"47","author":"de Vos-Geelen","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110955","article-title":"Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis","volume":"124","author":"Deng","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105639_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105639_bib17","first-page":"2026","article-title":"Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysis","volume":"17","author":"Fan","year":"2026","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105639_bib18","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105639_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1646568","article-title":"Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma","volume":"16","author":"Hong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib20","article-title":"Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib21","article-title":"Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105639_bib22","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105639_bib23","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1200\/JCO.2003.03.055","article-title":"Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus","volume":"21","author":"Ishikura","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2024.101152","article-title":"Current landscape of targeted therapy in esophageal squamous cell carcinoma","volume":"53","author":"Jubashi","year":"2024","journal-title":"Curr. Probl. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105639_bib25","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105639_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105639_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-024-03649-x","article-title":"Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study","volume":"73","author":"Lian","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2025.2564018","article-title":"Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients","volume":"11","author":"Liu","year":"2025","journal-title":"Future Sci. OA"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105639_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-019-1270-8","article-title":"Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus","volume":"14","author":"M\u00fcnch","year":"2019","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103689","article-title":"Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial","volume":"91","author":"Nomura","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105639_bib32","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105639_bib33","article-title":"Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase \u2161 trial","volume":"41","author":"Peng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib34","article-title":"Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives","volume":"49","author":"Prades-Sagarra","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105639_bib35","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","article-title":"Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus","volume":"23","author":"Stahl","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"10302","key":"10.1016\/j.critrevonc.2026.105639_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105639_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.157096","article-title":"Clinical observation of anti-PD-1\/PD-L1 immunotherapy plus concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"198","author":"Sun","year":"2026","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2025.09.008","article-title":"ESMO\u2013ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","volume":"37","author":"van Aken","year":"2026","journal-title":"Ann. Oncol."},{"issue":"1076","key":"10.1016\/j.critrevonc.2026.105639_bib39","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: the past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12885-025-13457-w","article-title":"The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105639_bib41","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-24-1236","article-title":"Chemoradiotherapy and subsequent immunochemotherapy as conversion therapy in unresectable locally advanced esophageal squamous cell carcinoma: a phase II NEXUS-1 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105639_bib42","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/cncr.26586","article-title":"Failure patterns in patients with esophageal cancer treated with definitive chemoradiation","volume":"118","author":"Welsh","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105639_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104371","article-title":"Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma","volume":"86","author":"Wen","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105639_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00262-025-04261-3","article-title":"Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: a multicenter retrospective study","volume":"75","author":"Wen","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105639_bib45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/cncr.33424","article-title":"Immunotherapy and radiation therapy sequencing: state of the data on timing, efficacy, and safety","volume":"127","author":"Williamson","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105639_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4061","article-title":"Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial","author":"Xi","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib47","article-title":"Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma","volume":"14","author":"Xie","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.07.413","article-title":"Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study","author":"Xu","year":"2026","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105639_bib49","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105639_bib50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2504726","article-title":"Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study","volume":"26","author":"Yang","year":"2025","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105639_bib52","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.21037\/tcr-20-2210","article-title":"A narrative review of combining radiation and immunotherapy in gastroesophageal cancers","volume":"10","author":"Yoon","year":"2021","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105639_bib53","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2022.11.006","article-title":"High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial","volume":"115","author":"You","year":"2023","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"key":"10.1016\/j.critrevonc.2026.105639_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115666","article-title":"Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study","volume":"167","author":"Yu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105639_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101366","article-title":"Radiotherapy: brightness and darkness in the era of immunotherapy","volume":"19","author":"Zhai","year":"2022","journal-title":"Transl. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105639_bib56","doi-asserted-by":"crossref","first-page":"708","DOI":"10.21037\/atm-22-2779","article-title":"Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105639_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103758","article-title":"Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial","volume":"92","author":"Zhang","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105639_bib58","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1038\/s41467-021-25539-x","article-title":"Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105639_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:46:30Z","timestamp":1791499590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"alternative-id":["S1040842826005263"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105639","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of immune-checkpoint inhibitors in combination with definitive chemoradiotherapy in non-metastatic esophageal SCC: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105639"}}